Biogen appoints Christopher Viehbacher as President and CEO
Viehbacher brings extensive international experience in large pharmaceutical and entrepreneurial biotech companies
Viehbacher brings extensive international experience in large pharmaceutical and entrepreneurial biotech companies
This is the first injectable product approval from our General Sterile Facility (F-3) which was inspected in August, 2022.
It allows users to generate cell lines suitable for clinical development without their own starter cells, vectors or prior experience in the field.
The JUMP-CP Consortium’s aim is to validate and scale up image-based drug discovery strategies by creating the world’s largest public cell imaging data set
Ketorolac Tromethamine Tablets are indicated to relieve moderately severe pain, usually after surgery.
The new plant will include a wide range of dosage form capabilities for oral solids, liquids, topicals, films, and manufacturing technologies for granulation, film coating, spray drying, tableting
Revenue from operations up 26% to Rs. 768 crores
He also highlighted the need for community awareness for continued implementation of the Covid Appropriate Behaviour (CAB) especially in view of the upcoming festival season
For the last ten financial years, the company has posted healthy performance with its revenue from operations growing at 15% CAGR and net profit at 23% CAGR
Subscribe To Our Newsletter & Stay Updated